Skip to main content
. Author manuscript; available in PMC: 2009 Jan 30.
Published in final edited form as: Vaccine. 2007 Dec 4;26(5):664–676. doi: 10.1016/j.vaccine.2007.11.045

Table 1.

Summary of results

Virus IC LD50 (pfu) IN LD50 (pfu) SCID pathogenesis IN protective dose (pfu) Efficacya
wt VACV 102 4 × 103 ++++ nd nd
VACVE3LA83N 3 × 104 4 × 107 +++ 100 4 × 105
VACVE3LA7C 106 to 107 >107 ++ 100–1000 >104 to 105
VACVE3LA54N 8 × 106 >107 + 20,000 >5 × 102
VACVAE3L∷Orf E3L >107 >107 +++ 100 >105
VACVAE3L >106 >107 1000 >104
a

Efficacy is defined as IN LD50/IN protective dose.